ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 516

The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study

Shinya Hirabara1, Toshihisa Kojima2, Nobunori Takahashi2, Yuji Hirano1, Atsushi Kaneko3, Daihei Kida4, Yasuhide Kanayama5 and Naoki Ishiguro2, 1Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, 4Orthopedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, 5Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Abatacept, methotrexate (MTX), pulmonary complications, rheumatoid arthritis (RA) and safety

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often becomes problematic for RA treatment. Abatacept (ABT) has been reported to have relatively few adverse events, and is often used in clinical settings in patients with pulmonary complications. Given the paucity of studies on the safety of ABT, however, accumulation of safety data under actual clinical settings is warranted. In the present study, we examined the persistence rates and treatment effects of ABT in patients with pulmonary complications.

Methods: We divided 250 RA patients registered in the Tsurumai Biologics Communication Registry who used ABT for ≥52 weeks according to whether they had pulmonary complications (L group: n=32) or not (N group: n=218). We then compared the persistence rates, incidence of adverse events, and disease activity between the two groups.

Results: No significant differences were found between groups with regard to mean age (L group, 67.7±6.9; N group, 64.0±12.8), disease duration (L group, 12.6±9.8; N group, 11.8±8.8), concomitant use rates of steroid (L group, 62.5%; N group, 60.5%), CRP (L group, 2.6±2.9; N group, 2.1±2.8), DAS28-CRP (L group, 4.7±1.5; N group, 4.4±1.3), or SDAI (L group, 28.8±16.5; N group, 24.5±14.0) at the time ABT was initiated, but significant differences were found in the percentage of women (L group, 65.6%; N group, 83.5%) and concomitant use rates of MTX (L group, 25%; N group, 53.2%). The persistence rates for 52 weeks were 73.1% and 74.3% in the L and N groups, respectively (Figure 1a). Adverse events occurred in 1 (3.13%) and 7 (3.83%) patients in the L and N groups, respectively. No pulmonary complications occurred after ABT administration in the L group, but 2 patients in the N group had interstitial pneumonia. Treatment was discontinued due to insufficient response in 6 (18.8%) and 29 (15.9%) patients in the L and N groups, respectively. None of these were significantly different by group. Mean DAS28-CRP significantly improved in both groups (Figure 1b), from 4.7 at ABT initiation to 3.2 at 52 weeks in the L group (P<0.01), and from 4.4 to 3.1 in the N group (P=0.034). Achievement of those with low disease activity also increased, from 9.4% at ABT initiation to 53.3% at 52 weeks in the L group, and from 8.3% to 47.7% in the N group.

Conclusion: The safety, treatment effects, and persistence rates of ABT were similar among RA patients with and without pulmonary complications. Use of ABT is beneficial even in patients with pulmonary complications, under close consideration of the risks involved.


Disclosure:

S. Hirabara,
None;

T. Kojima,

Takeda Pharma Corporation, Janssen Pharmaceutical, and Astellas Pharma Corporation.,

2,

Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Abbvie, Bristol-Myers Squibb、Pfizer and Chugai Pharma Corporation,

8;

N. Takahashi,

Abbott Japan Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Co. Ltd, Chugai Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. ,

8;

Y. Hirano,

AbbVie Inc.; Eisai Co. Ltd.; Mitsubishi Tanabe Pharma Corporation; Takeda Pharma Corporation; Pfizer Co. Ltd; Chugai Pharmaceutical Co. Ltd. and Bristol-Myers Squibb Co. Ltd.,

8;

A. Kaneko,

Janssen Pharmaceutica Product, L.P.,

8,

Astellas Pharma,

8,

Mitsubishi-Tanabe Pharma,

8,

Chugai,

8,

Eisai,

8,

Abbott Immunology Pharmaceuticals,

8,

Bristol-Myers Squibb,

8;

D. Kida,
None;

Y. Kanayama,

Astellas Pharma,

8,

Eisai,

8,

Mitsubishi Tanabe Pharma Corporation,

8,

AbbVie Inc,

8,

Chugai,

8;

N. Ishiguro,

AbbVie, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi Tanabe, Pfizer and Takeda.,

5,

AbbVie, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi Tanabe, Pfizer and Takeda.,

8.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-safety-and-treatment-efficacy-of-abatacept-in-rheumatoid-arthritis-patients-with-pulmonary-complications-from-the-tsurumai-biologics-communication-registry-tbcr-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies